2011
DOI: 10.1203/pdr.0b013e3182226a0c
|View full text |Cite
|
Sign up to set email alerts
|

11β–Hydroxysteroid Dehydrogenase Type 1 Activity in Short Small-For-GA Children and in Response to GH Therapy

Abstract: Small for GA (SGA) children are at risk for developing the metabolic syndrome. Those who do not catch up, and remain short (SSGA), may benefit from GH therapy. 11␤ Hydroxysteroid dehydrogenase type 1 (11␤-HSD-1) is expressed in visceral fat and is implicated in metabolic morbidity. We hypothesized that SSGA children will have increased basal and glucocorticoid (GC)-stimulated 11␤-HSD-1 activity. Twenty SSGA children, aged 7.1 Ϯ 1 y (mean Ϯ SD), were studied before and while on GH therapy and compared with 12 n… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
2
0

Year Published

2012
2012
2020
2020

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(3 citation statements)
references
References 55 publications
1
2
0
Order By: Relevance
“…The overexpression of isoform HSD11B1 in >37 weeks gestation neonates is in line with published observations [26]. It is tempting to speculate whether enzymatic activities of the HSD11 isoforms are changed in a gestational age dependent manner, as this has been demonstrated in children born small for gestational age with lack of catch-up growth who were found to have lower activity of HSD11B1 [77].…”
Section: Discussionsupporting
confidence: 87%
“…The overexpression of isoform HSD11B1 in >37 weeks gestation neonates is in line with published observations [26]. It is tempting to speculate whether enzymatic activities of the HSD11 isoforms are changed in a gestational age dependent manner, as this has been demonstrated in children born small for gestational age with lack of catch-up growth who were found to have lower activity of HSD11B1 [77].…”
Section: Discussionsupporting
confidence: 87%
“…In a study involving prepubertal children with short stature, a 4-wk challenge with GH caused reproducible changes in body fluid handling: there was a decrease in fractional excretion of water and increase in serum aldosterone (46), an intriguing observation given the relationship between secondary aldosteronism and pediatric PTCS (see above). Another study illustrated that GH therapy suppressed basal and glucocorticoid-stimulated HSD1 activity which may directly induce a relative cortisol deficiency (47). …”
Section: Association Of Ptcs and Endocrinopathiesmentioning
confidence: 99%
“…In addition, placental HSD11B2 expression and activity has been associated with infant birth weight and fetal growth [22], as well as preeclampsia [16,17]. Lowered placental HSD11B1 activity at birth has also been linked to reduced childhood growth of small for gestational age (SGA) infants at 7 yr of age, implicating it in postnatal growth [23]. There are, however, no published data comprehensively investigating DNA methylation, expression, and the interplay between the two HSD11B isoforms on birth weight.…”
Section: Introductionmentioning
confidence: 99%